Mi-Prostate Score test improves on PSA for predicting cancer
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.
The reason is that the traditionalprostate cancer screening test – a blood test to measure prostate specific antigen, or PSA – does not give doctors a complete picture.
Now, the University of Michigan Health System has begun offering a new urine test called Mi-Prostate Score to improve on PSA screening for prostate cancer. The test incorporates three specific markers that could indicate cancer and studies have shown that the combination is far more accurate than PSA alone.
“Many more men have elevated PSA than actually have cancer but it can be difficult to determine this without biopsy. We need new tools to help patients and doctors make better decisions about what to do if serum PSA is elevated. Mi-Prostate Score helps with this,” says Scott Tomlins, M.D., Ph.D., assistant professor of pathology and urology at the University of Michigan.
Researchers validated the new test on nearly 2,000 urine samples. Mi-Prostate Score, or MiPS, was significantly more accurate than PSA alone for predicting cancer as well as predicting aggressive prostate cancer that is likely to grow and spread quickly.
Mi-Prostate Score developed from a discovery in the lab of Arul Chinnaiyan, M.D., Ph.D., in 2005 of a genetic anomaly that occurs in about half of all prostate cancers, an instance of two genes changing places and fusing together.
This gene fusion, T2:ERG, is believed to cause prostate cancer. Studies in prostate tissues show that the gene fusion almost always indicates cancer.
The new urine test looks for the T2:ERG fusion as well as another marker, PCA3. This is combined with serum PSA measure to produce a risk assessment for prostate cancer. The test also predicts risk for having an aggressive tumor, helping doctors and patients make decisions about whether to wait and monitor test levels or pursue immediate biopsy.
“This combination test is not designed to say definitively at diagnosis whether a man has aggressive prostate cancer, but it can provide a more accurate estimate of the likelihood of having cancer and the likelihood of that cancer being aggressive,” Tomlins says.
The Latest on: Prostate cancer
- ‘Search and destroy’ radioactive treatment could extend lives of patients with incurable prostate cancer on June 2, 2019 at 2:36 pm
A “SEARCH and destroy” radioactive treatment could extend the lives of patients with incurable prostate cancer. Early results show men with no other options could get more than two years’ extra life. ... […]
- Treating incurable prostate cancer earlier could cut the chance of early death by a third, major trial finds on June 2, 2019 at 2:02 pm
The first two UK patients were treated last weekend, after research found that it could significantly extend survival for those with no other treatment options. Charities said they were “thrilled” by ... […]
- New 'hunt and destroy' radiotherapy treatment poised to tackle prostate cancer on June 2, 2019 at 2:00 pm
A pioneering treatment which can “search and destroy” cancer cells offers hope to thousands of patients. The targeted radiotherapy can tackle incurable prostate cancer when tumours have spread through ... […]
- Drugs make headway against lung, breast, prostate cancers on June 2, 2019 at 12:20 pm
CHICAGO (AP) - Newer drugs are substantially improving the chances of survival for some people with hard-to-treat forms of lung, breast and prostate cancer, doctors reported at the world's largest ... […]
- Men choosing active prostate cancer surveillance show low rates of follow-up monitoring on June 2, 2019 at 11:05 am
CHICAGO — Most men who choose active surveillance of prostate cancer fail to undergo guideline-recommended monitoring by year 2 after diagnosis, according to study data presented at ASCO Annual ... […]
- Could 2 Prostate Cancer Drugs Fight Disease in Earlier Stages? on June 2, 2019 at 6:36 am
SUNDAY, June 2, 2019 (HealthDay News) -- Cutting-edge prostate cancer drugs that help extend life in the toughest cases might also be useful in fighting less aggressive tumors, two new clinical trials ... […]
- ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approval on June 2, 2019 at 4:30 am
CHICAGO—Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they say Sunday's new data complements the supporting evidence they’ve already generated. Sunday at the ... […]
- Beating prostate cancer has given Phillies broadcaster Larry Andersen a new perspective on May 31, 2019 at 9:03 am
Larry Andersen picked up the phone that November morning and within seconds he darted a glance across the bedroom at his wife, Kristi. The look said it. It was a frightened, on-the-verge-of-tears mien ... […]
- Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase on May 31, 2019 at 7:23 am
Gram-negative bacteria have been found to be a major population in prostatitis and prostate cancer (PCa) tissues. Lipopolysaccharide (LPS), a major compound of Gram-negative bacteria, with stimulatory ... […]
- Race disparity in U.S. prostate cancer deaths disappears with equal care on May 30, 2019 at 10:19 am
(Reuters Health) - Black men are more likely to die of prostate cancer than white men in the U.S., but a new study suggests this racial disparity may be largely due to differences in the medical care ... […]
via Google News and Bing News